Whenever we give medication to a large portion of the population without long-term safety, one is concerned about what those long-term safety signals are going to be.” “COPD exacerbations ...

Study objectives: To identify the predictors of medication adherence in patients with COPD and contrast the health beliefs, experiences, and behaviors of COPD patients self-reporting good ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Aegis Sciences Corporation, a leading provider of innovative toxicology and healthcare testing solutions, proudly announces ...

The shares of Senores Pharmaceuticals Limited were trading at ₹570.70 up by ₹36.90 or 6.91% on the NSE today at 2.32 pm.

or GLP-1 receptor agonist after 2013 and who had active COPD as indicated by multiple outpatient or at least one inpatient diagnosis. Patients were divided into drug class groups and matched by a ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

A new study published in the CHEST journal found that ensifentrine, an innovative inhaled therapy, significantly reduces the ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...